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We assessed the cost-effectiveness of including boys vs girls alone in a pre-adolescent vaccination programme against human
papillomavirus (HPV) types 16 and 18 in Brazil. Using demographic, epidemiological, and cancer data from Brazil, we developed a
dynamic transmission model of HPV infection between males and females. Model-projected reductions in HPV incidence under
different vaccination scenarios were applied to a stochastic model of cervical carcinogenesis to project lifetime costs and benefits. We
assumed vaccination prevented HPV-16 and -18 infections in individuals not previously infected, and protection was lifelong.
Coverage was varied from 0-90% in both genders, and cost per-vaccinated individual was varied from I$25 to 400. At 90% coverage,
vaccinating girls alone reduced cancer risk by 63%; including boys at this coverage level provided only 4% further cancer reduction. At
a cost per-vaccinated individual of $50, vaccinating girls alone was o$200 per year of life saved (YLS), while including boys ranged
from $810–18650 per YLS depending on coverage. For all coverage levels, increasing coverage in girls was more effective and less
costly than including boys in the vaccination programme. In a resource-constrained setting such as Brazil, our results support that the
first priority in reducing cervical cancer mortality should be to vaccinate pre-adolescent girls.
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Cervical cancer is the second most common cancer in women
worldwide (Parkin and Bray, 2006), with the majority of cases and
deaths occurring in low-resource countries where organised
screening has not been feasible, for example, nearly 20000 women
in Brazil are predicted to develop cervical cancer over the next year
(Ferlay et al, 2004). Vaccines designed to prevent infections with
human papillomavirus (HPV)-16 and -18, responsible for roughly
70% of cases, provide an opportunity for primary prevention.
Clinical trials of these vaccines have shown a high degree of
efficacy at preventing types 16 and 18 associated infection and
precancerous changes in women not previously infected with these
types (Harper et al, 2006; Ault, 2007; Future II Study Group, 2007;
Garland et al, 2007; Paavonen et al, 2007).
Reductions in cervical cancer mortality by pre-adolescent HPV
vaccination would not be observable for many years. Mathematical
models that synthesize the best available data while ensuring
consistency with epidemiological observations can project out-
comes beyond those reported in clinical trials, can provide insights
into cost-effectiveness, and can be modified as new information
becomes available (Garnett et al, 2006; Goldie et al, 2007). We
recently used an empirically calibrated stochastic model of cervical
cancer in a cost-effectiveness analysis of pre-adolescent vaccina-
tion of Brazilian girls, with specific attention to strategies that
include screening (Goldie et al, 2007). Because HPV is sexually
transmitted, vaccination of both sexes is being considered in some
settings.
To assess the value of including boys in a vaccination
programme, a dynamic transmission model is required, which
captures not only the direct protective effects on vaccinated
individuals, but also the potential indirect effects of reducing HPV
transmission to their partners (Edmunds et al, 1999; Brisson and
Edmunds, 2003; Garnett, 2005). Extending previous work by others
(Hughes et al, 2002; Taira et al, 2004; Elbasha and Galvani, 2005;
Barnabas et al, 2006; Dasbach et al, 2006; French et al, 2007), we
developed a flexible dynamic model of HPV-16 and -18 sexual
transmission between males and females. We linked this model to
our stochastic model of cervical carcinogenesis that includes non-
vaccine targeted (i.e., non-16, -18) high- and low-risk HPV types to
assess the cost-effectiveness of including boys in a pre-adolescent
vaccination programme in Brazil.
MATERIALS AND METHODS
Dynamic model
A simplified schematic of the dynamic transmission model is
shown in Figure 1. It is an open-cohort, age-structured (ages 0–90
in yearly intervals) compartmental model in which females and
males form sexual partnerships over time. Sexually-naive girls and
boys enter the susceptible pool upon sexual initiation starting
at age 12, and with each partnership, HPV-16 and -18 can
be transmitted. Following first HPV infection and clearance,
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tively reducing their susceptibility to future same-type infection.
Women with HPV infection can develop cervical intraepithelial
neoplasia, grade 1 (CIN 1) or grade 2–3 (CIN 2,3), and those with
CIN 2,3 may develop invasive cancer. Males can acquire HPV
infection from infected females with or without CIN.
Input parameters for the model were estimated using primary
data from longitudinal epidemiological studies and other pub-
lished literature, and for some inputs, were indirectly estimated
using calibration methods. Population and demographic statistics
from Brazil were used to inform population size, and birth and
death rates (U.S. Census Bureau, 2000; U.N. Population Division,
2004). We adapted a previously published sexual mixing algorithm
(Barnabas et al, 2006) to reflect data on sexual behaviour in Brazil,
such as age of sexual debut and number of sexual partners
(U.S.A.I.D., 2006). Briefly, depending on age, members of the male
and female cohorts belong to one of four sexual activity groups
(none, low, moderate, and high), which govern the number of new
sexual partners per year. Each year, type-specific HPV incidence
changes according to the number of new partners, HPV prevalence
in the opposite gender, and the probability of HPV transmission
given a partner has HPV-16 or -18 infection. Details of model
structure, input parameters and sexual mixing assumptions are
provided in the Supplementary information.
A likelihood-based calibration exercise was used to identify
combinations of four uncertain parameter values that produced
good model fit to empirical data. These parameters included (1)
transmission probability of HPV-16 per infected-susceptible
partnership, (2) transmission probability of HPV-18 per in-
fected-susceptible partnership, (3) clearance rate of HPV-16 and
-18 infection, and (4) progression rate of CIN 2,3 to invasive
cancer. We employed the following approach: more than 100000
model simulations were run in the absence of vaccination or
screening. For each simulation, one value for each of the four
parameters was randomly selected from a uniform distribution
over pre-specified plausible ranges, creating a unique natural
history parameter set. Model outcomes using each parameter set
were scored according to their fit with calibration targets
established using epidemiological data from studies in Brazil and
other South American countries. Good-fitting sets were identified
based on a composite goodness-of-fit score. Details of these
methods are provided in the Supplementary information.
Using the best-fitting parameter set, we projected reductions in
HPV-16 and -18 incidence that would be expected over time with
and without HPV vaccination of pre-adolescent girls alone vs boys
and girls. We assumed vaccination occurred in girls and boys
before age 12 and provided lifetime protection against all incident
HPV-16 and -18 infections. Coverage rates were varied from 0 to
90% in girls and boys independently. After the epidemic achieved
equilibrium post-vaccination, age-specific incidence rates of
HPV-16 and -18 were generated for each vaccination scenario.
The reductions in HPV incidence projected from the dynamic
transmission model were then used as direct inputs to our
previously described stochastic model (Goldie et al, 2007;
Kim et al, 2007). The latter model differs from the dynamic
transmission model in the following ways: (1) only females are
represented; (2) all HPV types (both vaccine-targeted and non-
targeted) are included; (3) HPV incidence is a function of age and
individual-level characteristics, but does not explicitly change over
time in response to sexual activity and population prevalence; (4)
it is an individual-based model, which keeps track of each woman’s
history; and (5) it is stochastic, reflecting variability as well as
uncertainty. Like the dynamic transmission model, it is empirically
calibrated to epidemiological data (Goldie et al, 2007; Kim et al,
2007).
Cost-effectiveness analysis
Lifetime costs, life expectancy, and incremental cost-effectiveness
ratios were estimated for including boys in a vaccination
programme compared to girls alone. Estimations of costs (e.g.,
cancer treatment) are documented elsewhere (Goldie et al, 2007),
but briefly, we included direct medical costs, nonmedical costs,
and time costs. Since the price of the vaccine and cost of delivery
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Figure 1 Schematic of dynamic model for females. Females who are uninfected can acquire HPV-16 or -18 infection (at an annual rate of l16 or l18,
respectively). Once infected, females can develop precancerous lesions (i.e., CIN 1 and CIN 2,3), and over time may develop invasive cervical cancer.
Females who clear their infection or lesion develop a degree of natural immunity to that same HPV type (i.e., immune16 or immune18); future type-specific
infections can be acquired at a reduced rate (e.g., l16*(1-immune16)). History of prior infection is tracked throughout the analysis. Note: not all health states
and transitions are shown. The model for males has a similar structure for HPV-16 and -18 infection only (the schematic and corresponding model equations
can be found in the Supplementary information). Once vaccination is introduced, females and males enter a corresponding vaccinated state; vaccine efficacy
is modelled as protection against future type-specific infection.
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individual, which was varied from I$25 to 400; for example, for a
composite cost of $25 per-vaccinated individual, we assumed three
doses of vaccine at $5 each ($15), wastage of $2.25, freight and
supplies of $1.31, administration of $1.50, and vaccine support and
programmatic costs of $4.94 (Goldie et al, 2007). Costs are
presented in 2000 international dollars, a currency that provides a
means of comparing costs among countries, taking into account
differences in purchasing power (World Health Organization,
2007).
Following published guidelines for economic evaluations, we
adopted a societal perspective and included all costs and benefits
regardless to whom they accrue and discounted future costs and
life years by 3% annually (Gold et al, 1996). The performance of
alternative strategies was measured using the incremental cost-
effectiveness ratio, which is defined as the additional cost of a
specific strategy, divided by its additional benefit compared with
the next-most-expensive strategy. Strategies were excluded from
the cost-effectiveness calculations if they were more costly and less
effective (i.e., strongly dominated) or less costly and less cost-
effective (i.e., weakly dominated) than an alternative strategy. We
assessed the model’s internal consistency (against data used as
inputs), external consistency (against known facts about the
disease), projective validity (against data sourced independently
from model inputs), and convergent validity (against results from
different models) (Weinstein et al, 2003).
RESULTS
Model calibration and validity
The calibrated values of the four parameters in the best-fitting
parameter set, and the mean and range of values for the 10 best-
fitting sets, are presented in the Supplementary information.
Figure 2 shows examples of model output from the 10 sets with the
best goodness-of-fit scores compared with empirical prevalence
data of HPV-16 (upper panel) and -18 (lower panel) from two large
epidemiological studies in South America (Franco et al, 1999;
Molano et al, 2002; Clifford et al, 2005). External consistency of the
model was demonstrated by producing outcomes that were within
the 95% confidence intervals of independent data, including age-
specific cancer incidence rates (HPV-16 and -18 associated only)
(International Agency for Research on Cancer, 1976; Clifford et al,
2003ab, 2006) (Figure 3). Additional calibration results and an
assessment of projective validity are provided in the Supplementary
information.
Clinical benefits and cost-effectiveness of vaccination
Shown in Table 1 are the reductions in lifetime cancer risk and the
cost-effectiveness ratios associated with vaccinating both boys and
girls vs girls alone at different costs per-vaccinated individual
($25–400) and coverage rates (equal for both genders). In a
vaccination programme for pre-adolescent girls alone, benefits
were generally proportional to the level of coverage; for example,
reduction in overall cancer risk was 14% with 25% coverage, and
63% with 90% coverage. When boys were added to the vaccination
programme, cancer reduction was consistently higher than when
covering girls alone; however, the magnitude of the incremental
benefit of including boys depended on the level of coverage
achieved for girls. For example, at 50% coverage of girls, reduction
in lifetime risk of cancer increases from 29 to 40% when including
equal coverage of boys; in contrast, at 90% coverage, reduction in
cancer increases from 63 to 67% when including boys.
At a composite cost of $25 per-vaccinated individual (approxi-
mately $5 per dose), vaccinating pre-adolescent girls alone was
cost-saving compared to no vaccination, at all coverage levels.
When this cost increased to $50 (approximately $12 per dose),
vaccination was no longer cost-saving, and the cost-effectiveness
ratios varied by level of coverage; while vaccinating girls only was
consistently less than $200 per year of life saved (YLS), the ratio for
vaccinating both girls and boys increased from $810 per YLS to
$18650 per YLS, as coverage increased. This trend was consistent
at higher costs.
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Figure 2 Model output of age-specific prevalence of HPV-16 (upper
panel) and HPV-18 (lower panel) among females compared to empirical
data. Red dotted line represents model output for the best-fitting set; grey
lines represent model output for the next nine best-fitting sets. Black solid
lines depict the 95% confidence interval of the empirical data at each age
group (Franco et al, 1999; Molano et al, 2002; Clifford et al, 2005, 2006).
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Figure 3 Model output of age-specific incidence of cervical cancer
(HPV-16 and-18 associated only) compared to empirical data. Red dotted
line represents model output for the best-fitting set; grey lines represent
model output for the next nine best-fitting sets. Black solid lines depict the
95% confidence interval of the empirical data at each age group
(International Agency for Research on Cancer, 1976; Clifford et al,
2003a, b, 2006).
Cost-effectiveness analysis of HPV vaccination among boys
JJ Kim et al
1324
British Journal of Cancer (2007) 97(9), 1322–1328 & 2007 Cancer Research UK
E
p
i
d
e
m
i
o
l
o
g
yBecause countries may consider investments to increase vaccine
coverage, we explored the tradeoffs associated with increasing
coverage in girls vs including boys in a vaccination programme
(Table 2). At initial coverage levels of 25 or 75% for alone, a
strategy of including boys was always more costly and less effective
than increasing coverage for girls; for example, when considering
investments beyond 25% coverage in girls alone, a strategy of
increasing their coverage to 50% provided an 8% greater reduction
in cancer risk and was less costly than adding 25% coverage in
boys. Even with 75% coverage in girls, increasing their coverage to
90% was more effective and less costly than adding coverage of
boys up to 25, 50, or 75%.
Results of other sensitivity analyses, including varying assump-
tions about type-specific natural immunity, an increase in cancer
caused by non-vaccine targeted HPV types, cross-protection
extending to other HPV types, and waning vaccine immunity,
produced findings similar to those reported in previous analyses
(Goldie et al, 2007).
DISCUSSION
The goal of our analysis is to inform discussions about how best to
reduce deaths from cervical cancer in Brazil and epidemiologically
similar countries. Our results suggest that for a pre-adolescent
vaccination programme in which coverage of girls is high, the
added value of including boys will be relatively small compared
with settings in which coverage of girls is low. While there were
increased health benefits for females when boys were included
at any coverage level, the marginal impact on cervical cancer
incidence diminished as coverage in girls increased, while total
costs nearly doubled (assuming same coverage for both genders),
resulting in less attractive cost-effectiveness ratios. When we
comparatively assessed the impact of increasing coverage in girls
to including boys in the vaccination programme, we found that
even a modest increase in coverage of girls was less costly, yet
more beneficial, than covering an equal percentage of boys. In
other words, at any specific coverage level, a decision maker faced
Table 1 Clinical benefits and incremental cost-effectiveness ratios by vaccine coverage and cost per-vaccinated individual
a
Reduction in lifetime
cancer risk
b %
Cost per-vaccinated individual
c
$25 ($5 per dose) $50 ($12 per dose) $100 ($27 per dose) $400 ($115 per dose)
25% coverage
Girls only 14 Cost-saving
d 70 610 3450
Girls and boys 21 110 810 2190 9370
50% coverage
Girls only 29 Cost-saving
d 30 540 3210
Girls and boys 40 660 1740 3900 15120
75% coverage
Girls only 45 Cost-saving
d 130 740 3940
Girls and boys 57 2440 2180 4860 18820
90% coverage
Girls only 63 Cost-saving
d 170 810 4180
Girls and boys 67 9110 18650 37720 136910
aValues represent incremental cost-effectiveness ratios (additional cost divided by additional health benefit compared to the next best strategy) expressed as cost per year of life
saved (international dollar per YLS). Strategies including girls alone were compared to no vaccination.
bReduction in lifetime cancer risk for all strategies was calculated against no
vaccination.
cCost per-vaccinated individual includes three doses, wastage, delivery, and programmatic costs, and is expressed in 2000 international dollars.
dStrategies are
cost-saving compared to no vaccination because the future costs averted by preventing cancer are greater than the cost of vaccination.
Table 2 Tradeoff of increasing vaccine coverage of girls versus including boys
a
Reduction in lifetime
cancer risk
b % Total cost (I$)
Total life
expectancy (years)
Incremental cost-effectiveness
ratios (I$/YLS)
If we can achieve beyond 25% vaccine coverage in girls, should we invest in increasing coverage in girls (to 50%) or adding coverage of boys (to 25%)?
No vaccination — 58.47 39.9442 —
Increase girls: girls only (50%) 29 59.87 39.9928 30
Girls only (25%) 14 60.05 39.9671 Dominated
c
Add boys: girls (25%)+boys (25%) 21 67.33 39.9761 Dominated
c
If we can achieve beyond 75% vaccine coverage in girls, should we invest in increasing coverage in girls (to 90%) or including coverage of boys (to 25% or higher)?
No vaccination — 58.47 39.9442 —
Girls only (75%) 45 66.34 40.0051 130
Increase girls: girls only (90%) 63 71.20 40.0213 300
Add boys: girls (75%)+boys (25%) 48 76.23 40.0110 Dominated
c
Add boys: girls (75%)+boys (50%) 52 86.86 40.0135 Dominated
c
Add boys: girls (75%)+boys (75%) 57 96.72 40.0191 Dominated
c
aI$¼international dollar; YLS¼years of life saved. Analysis assumed cost per-vaccinated individual of $50 (i.e., $12 per dose). Strategies are listed by increasing total cost.
bReduction in lifetime cancer risk for all strategies was calculated against no vaccination.
c’Dominated’ strategies were more costly and less effective (i.e., strongly dominated) than
an alternative strategy of covering girls alone.
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boys should always increase coverage in girls first, all else being
equal.
The Commission on Macroeconomics and Health has suggested
that interventions with ratios below per capita GDP should be
considered ‘very cost-effective’ (World Health Organization, 2001).
For Brazil, this would imply a threshold of approximately I$ 8600
(U.S. Central Intelligence Agency, 2007). Some would argue that
the real-world threshold for a new programme should be the
incremental cost-effectiveness ratios of other public health
interventions competing for the same resources, such as vaccines
that have already been implemented. In this case, the relevant
threshold ratio could be as low as $500 per YLS (Jha et al, 1998).
Adopting this lower threshold would imply that the cost per-
vaccinated person would need to approximate or be lower than $50
for pre-adolescent vaccination of girls to be cost-effective. Further,
unless this cost is well below $50, coverage in girls is well below
50%, and coverage in girls could not be increased, then adding
boys to a vaccination programme may not be cost-effective in
Brazil. We acknowledge however, that cost-effectiveness is one of
the many factors that influence decision-making and that there
may be other considerations, such as equity, community perception,
cultural preferences, and political realities that will play a larger role.
As recommended in guidelines for health economic evaluations
(Gold et al, 1996), we adopted a societal perspective and
considered a long time horizon that captures not only the
immediate costs of vaccination, but also the future costs averted
by preventing cancer in later years. While cost-effectiveness
analysis provides information on ‘value for money’, it is not
equivalent to providing information on the budget impact to a
local decision maker. Although countries need to conduct their
own financial analyses, estimating the financial resources required
for a vaccination programme over the first few years can provide
useful, albeit daunting, qualitative insights. For example, at a cost
per-vaccinated girl of $100, vaccinating just 50% of 11-year-old
girls is projected to exceed $85 million in just the first year of the
programme. Adding boys at the same coverage level would double
the cost. Of note, because our analysis presents cost-effectiveness
results in international dollars, the relevant financial assessment
would convert the tradeable portion of the intervention cost (e.g.,
vaccine) using the foreign exchange rate, and express all costs in
local currency.
Our results associated with vaccinating girls alone were
consistent with those obtained in a previous analysis we conducted
in Brazil using our stochastic model of girls (Goldie et al, 2007). In
particular, we found that the cost-effectiveness of HPV vaccination
was most influenced by the vaccine price and cost of delivering
adolescent vaccination. Although dynamic transmission models of
HPV infection are increasingly being developed to explore the
population-level impact of an HPV vaccine, to date, there are few
that evaluate the cost-effectiveness of vaccinating both boys and
girls within vaccination programmes (Taira et al, 2004; Dasbach
et al, 2006; Elbasha et al, 2007; Newall et al, 2007), and none
pertaining to low-resource settings. These studies, conducted in
the context of current screening in the United States, have drawn
similar conclusions that vaccinating 12-year-old girls is an
attractive strategy. However, while Taira et al (2004) found that
including boys in a vaccination programme costs nearly $450000
per quality-adjusted life years (QALY) gained, Elbasha et al (2007)
concluded that vaccinating both boys and girls, with catch-up
programmes up to age 24 for both sexes, costs $45100 per QALY.
Although Elbasha et al (2007) capture the vaccine benefits of
reducing HPV-6 and -11 related sequelae, they do not incorporate
the impact of the vaccine on overall cancer incidence associated
with all HPV types. Similar to Taira et al (2004), we employed two
distinct types of models to address this issue and capitalise on
the strengths of each. In the dynamic model, we reflected the
infectious transmission of HPV-16 and -18 among sexually active
males and females to capture herd immunity effects, and in the
stochastic model, we translated the benefits of a vaccine targeting
two types of HPV to overall cancer incidence associated with all
high-risk HPV types.
As with all modelling approaches there are limitations to our
analysis that should be noted. First, like others (Hughes et al, 2002;
Barnabas et al, 2006; Burchell et al, 2006), we indirectly estimated
HPV transmission probabilities per infected-susceptible partner-
ship. Although similar to the calibrated estimates of transmission
per coital act by Burchell et al (2006), our calibrated values of
transmission probability per infected-susceptible partnership for
HPV-16 and -18 were lower than those estimated from other
studies (Hughes et al, 2002; Barnabas et al, 2006); however, we
modelled a different population with different HPV prevalence and
sexual behaviours and allowed other uncertain variables, such as
HPV clearance and CIN 2,3 progression to cancer, to simulta-
neously vary in the fitting process, as well. As better data become
available on age- and gender-specific transmission, it will be
important to reassess these estimates.
As we await data on vaccine efficacy in boys, we made an
assumption that the vaccine was as efficacious in reducing HPV-16
and -18 incidence among boys as it is for girls. Even under such
generous assumptions, we found that investing in increased
coverage of girls was far more favourable than including boys in
a vaccination programme. We did not, however, consider the
potential benefits of the quadrivalent HPV vaccine in preventing
HPV-6 and -11 associated genital warts, as our analysis was
explicitly focused on reducing cervical cancer mortality; any
positive externalities that are not included in the analysis would
improve the cost-effectiveness of the vaccine in the overall
population. We did not include other cancers associated with
HPV-16 and -18, as data in Brazil are limited, and also because
their natural histories are not well-elucidated to model over
decades. Detailed sexual behaviour data are limited. Not only is
there severe under-reporting and misreporting of sexual beha-
viour, but there are also significant time trends that may be
occurring in developing countries with respect to age of sexual
initiation and number of partners that can impact overall
incidence of HPV. To the extent that childhood exposure to
HPV (e.g., from sexual abuse or mother-to-child transmission),
and in particular HPV-16 and -18, is underestimated, we may be
overestimating the protective effects of the vaccine. We did not
model bisexual or homosexual partnerships, nor did we include
risk factors that may be changing over time, such as smoking (Ho
et al, 1998; Munoz et al, 2006).
We assumed individuals had an equal chance of getting
vaccinated, but in reality, uptake may be lower in settings with
less access to adolescents, such as rural areas and where children
are not in school. It will therefore be important to monitor
differential uptake and post-vaccination behaviour. Finally, as we
have previously reported, potentially influential uncertainties such
as the duration of vaccine efficacy, magnitude of herd immunity,
cross protection, interactions between HPV types and natural
history of multiple infections all represent data gaps; modelled
estimates will improve as better information becomes available.
In light of the range of uncertainties and the unavoidable
limitations inherent in modelling methods, we present our findings
as exploratory and aim to provide qualitative insight into decisions
that countries will be facing in the coming years regarding HPV
vaccine implementation. On the basis of the most current
epidemiological data, the results of this analysis suggest that the
benefits of including boys in an HPV vaccination programme
depend on the level of coverage achievable for girls, and in
particular, the added benefit on cancer reduction is relatively small
provided coverage of girls is greater than 75%. Moreover, even at
this coverage level, expanding coverage in girls is more cost-
effective than adding boys to the vaccination programme. In a
resource-constrained setting such as Brazil, our results support
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be to vaccinate pre-adolescent girls.
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